MarketCapExport financials
Olema Pharmaceuticals (OLMA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Olema Pharmaceuticals Balance Sheet 2025-2011 | OLMA
Brief overview of Olema Pharmaceuticals's balance sheet strength
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets advanced +80.2% to $533.4 million from $295.9 million; annual growth near 15.9% reflects a fast increase in scale.
Asset growth of +80.2% came with a +382.3% rise in liabilities. Financial leverage became more prominent.
Equity accounts for 89.7% of assets. Against the initial 96.2%, the capital position looks resilient.
The period ended with net cash: net debt stood at -$47.1 million. This supports financial flexibility.
The cash share moved from 4.7% to 9.1%. A higher figure generally provides more room in an adverse scenario.
Retained earnings remain negative at -$597.6 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
What the balance sheet shows
Olema Pharmaceuticals retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.
Annual Balance Sheet Olema Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-47.1 M | -138 M | -66.1 M | -21.1 M | -10.5 M | -339 M | -68 K | -3.15 M | - | - | - | - | - | - | - |
Long Term Debt |
69 K | 257 K | 1.43 M | 1.55 M | 2.36 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.12 M | 1.17 M | 988 K | 1.02 M | 931 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 9.35 M | 9.35 M | - | - | - | - | - | - | - |
Total Current Liabilities |
51.8 M | 41.8 M | 21.6 M | 16.5 M | 9.02 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
54.9 M | 42 M | 23 M | 18.1 M | 11.4 M | 4.58 M | 10.7 M | 9.55 M | - | - | - | - | - | - | - |
Retained Earnings |
-598 M | -435 M | -306 M | -209 M | -104 M | - | -10.8 M | -6.45 M | - | - | - | - | - | - | - |
Total Assets |
533 M | 451 M | 277 M | 216 M | 296 M | 343 M | 132 K | 3.27 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
48.3 M | 139 M | 68.5 M | 23.7 M | 13.8 M | 339 M | - | - | - | - | - | - | - | - | - |
Book Value |
479 M | 409 M | 254 M | 198 M | 285 M | 338 M | -10.6 M | -6.28 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
479 M | 409 M | 254 M | 198 M | 285 M | 338 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Olema Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
69 K | - | 257 K | 310 K | 602 K | 123 K | 257 K | 562 K | 859 K | 1.15 M | 1.43 M | 1.7 M | 1.21 M | 1.38 M | 1.55 M | 1.75 M | 2.01 M | 2.16 M | 2.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
54.9 M | 50.2 M | 42 M | 45 M | 36.8 M | 26.2 M | 42 M | 31.3 M | 27.4 M | 27.4 M | 23 M | 17.7 M | 16 M | 20.8 M | 18.1 M | 14.3 M | 14.3 M | 12.3 M | 11.4 M | 8.9 M | 8.15 M | 5.28 M | 4.58 M | 4.58 M | 4.58 M | 4.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-598 M | -651 M | -435 M | -551 M | -509 M | -465 M | -435 M | -402 M | -367 M | -337 M | -306 M | -279 M | -257 M | -237 M | -209 M | -183 M | -160 M | -127 M | -104 M | -82.6 M | -64.8 M | -48.4 M | -33.1 M | -33.1 M | -33.1 M | -33.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
533 M | 531 M | 451 M | 352 M | 382 M | 410 M | 451 M | 230 M | 255 M | 264 M | 277 M | 293 M | 178 M | 196 M | 216 M | 232 M | 251 M | 277 M | 296 M | 310 M | 322 M | 331 M | 343 M | 343 M | 343 M | 343 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
139 M | 52.5 M | 68.5 M | 35.3 M | 52.5 M | 50.6 M | 139 M | 35.9 M | 16.9 M | 33.7 M | 68.5 M | 117 M | 35 M | 40.9 M | 23.7 M | 26.8 M | 24.5 M | 21.5 M | 13.8 M | 25.6 M | 50.4 M | 47.9 M | 339 M | 339 M | 339 M | 339 M | 68 K | - | - | - | 3.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
479 M | 480 M | 409 M | 307 M | 345 M | 383 M | 409 M | 199 M | 227 M | 236 M | 254 M | 275 M | 162 M | 175 M | 198 M | 218 M | 236 M | 265 M | 285 M | 301 M | 314 M | 326 M | 338 M | 338 M | 338 M | 338 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
409 M | 480 M | 254 M | 307 M | 345 M | 383 M | 409 M | 199 M | 227 M | 236 M | 254 M | 275 M | 162 M | 175 M | 198 M | 218 M | 236 M | 265 M | 285 M | 301 M | 314 M | 326 M | 338 M | 338 M | 338 M | 338 M | -10.6 M | - | - | - | -8.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Olema Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
USA
Russia
Niderland
France
Israel
Australia
Britain
